Beam Therapeutics Inc.
Stock Details
Is it expensive?
Trailing P/E Ratio
-37.21
Forward P/E Ratio
-6.88
PEG Ratio
0.12
-5.27
Price-to-Sales (TTM)
22.00
2.42
12.48
Market Cap
3.07B
1.91B
Is it profitable?
Net Profit Margin (TTM)
-57.24%
Gross Profit Margin
0.00%
Diluted EPS (TTM)
-0.81
-8.11%
139.74M
Is it growing?
279.50%
279.52%
Is it risky?
2.19
12.45
13.09
154.12M
Who owns it?
104.65%
1.38%
23.48%
101.75M
87.87M
Does it pay?
0.00%
0.00%
--
--
How much cash?
1.25B
-345.10M
-220.31M
12.54
- Price
- 30.68
- Percent Change
- +0.38 (1.25%)
- Previous Close
- 30.30
- Open
- 30.53
- Low
- 29.87
- High
- 31.40
52-Week Range Position (52WRP)
Above Average
Above Average
within its 1-year price range
$30.68
From 52W Low
+99.87%
From 52W High
-15.81%
Today
+1.25%
1Y Change
+84.60%
6M
$25.79
3M
$31.22
1M
$25.49
Today
$30.68
From 52W Low
+99.87%
From 52W High
-15.81%
Today
+1.25%
1Y Change
+84.60%
6M
$25.79
3M
$31.22
1M
$25.49
Today
$30.68
Above Average
within its 1-year price range
$30.68
Multi-Timeframe Analysis (MTA)
Uptrend
Most timeframes point up. One conflicting period introduces some uncertainty, but the overall direction is positive. Weaker than a Strong Uptrend, but still a bullish signal. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+20.4%
3M
-1.7%
6M
+19.0%
1Y
+84.6%
Rate of Change (ROC)
Accelerating
Price is rising 6.4x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Beam Therapeutics Inc.
- Founded
- Jan 1, 2017
- Founders
- David R. Liu, Feng Zhang, J. Keith Joung
- CEO
- John M. Evans
- Employees
- 511
- Fiscal Year End
- Dec 31, 2024
- Address
238 Main Street
Cambridge
Massachusetts
02142
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.beamtx.com
Indicators
Operating Cash Flow
-345.10M
Net Income
-79.99M
Real Earnings
4.31
Cash flow exceeds reported profit. Every dollar of profit is backed by actual cash. Only the most financially disciplined businesses consistently show this pattern.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Indicators
Operating Cash Flow
-345.10M
Net Income
-79.99M
Real Earnings
4.31
Cash flow exceeds reported profit. Every dollar of profit is backed by actual cash. Only the most financially disciplined businesses consistently show this pattern.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Stock Details
Is it expensive?
Trailing P/E Ratio
-37.21
Forward P/E Ratio
-6.88
PEG Ratio
0.12
-5.27
Price-to-Sales (TTM)
22.00
2.42
12.48
Market Cap
3.07B
1.91B
Is it profitable?
Net Profit Margin (TTM)
-57.24%
Gross Profit Margin
0.00%
Diluted EPS (TTM)
-0.81
-8.11%
139.74M
Is it growing?
279.50%
279.52%
Is it risky?
2.19
12.45
13.09
154.12M
Who owns it?
104.65%
1.38%
23.48%
101.75M
87.87M
Does it pay?
0.00%
0.00%
--
--
How much cash?
1.25B
-345.10M
-220.31M
12.54
- Price
- 30.68
- Percent Change
- +0.38 (1.25%)
- Previous Close
- 30.30
- Open
- 30.53
- Low
- 29.87
- High
- 31.40
52-Week Range Position (52WRP)
Above Average
Above Average
within its 1-year price range
$30.68
From 52W Low
+99.87%
From 52W High
-15.81%
Today
+1.25%
1Y Change
+84.60%
6M
$25.79
3M
$31.22
1M
$25.49
Today
$30.68
From 52W Low
+99.87%
From 52W High
-15.81%
Today
+1.25%
1Y Change
+84.60%
6M
$25.79
3M
$31.22
1M
$25.49
Today
$30.68
Above Average
within its 1-year price range
$30.68
Multi-Timeframe Analysis (MTA)
Uptrend
Most timeframes point up. One conflicting period introduces some uncertainty, but the overall direction is positive. Weaker than a Strong Uptrend, but still a bullish signal. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+20.4%
3M
-1.7%
6M
+19.0%
1Y
+84.6%
Rate of Change (ROC)
Accelerating
Price is rising 6.4x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Beam Therapeutics Inc.
- Founded
- Jan 1, 2017
- Founders
- David R. Liu, Feng Zhang, J. Keith Joung
- CEO
- John M. Evans
- Employees
- 511
- Fiscal Year End
- Dec 31, 2024
- Address
238 Main Street
Cambridge
Massachusetts
02142
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.beamtx.com